Literature DB >> 7905189

Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine.

A F Arnsten1, J X Cai.   

Abstract

Very low doses (0.00001 mg/kg) of the alpha-2 adrenergic antagonist, yohimbine, improved working memory performance in a subset of aged monkeys. Improvement appeared to result from increased norepinephrine (NE) release onto postsynaptic alpha-2 adrenoceptors, as the response was blocked by the "postsynaptic" alpha-2 antagonist, SKF104078. Cognitive-enhancing effects of low dose yohimbine treatment may depend on aged animals retaining an intact, endogenous NE system. In contrast to yohimbine, the alpha-2 agonist, clonidine, has improved working memory in all aged animals examined. In the present study, clonidine's beneficial effects were also blocked by the postsynaptic antagonists SKF104078 and SKF104856, suggesting that clonidine acts by directly stimulating postsynaptic alpha-2 adrenoceptors. Beneficial doses of clonidine (0.01 mg/kg) and yohimbine (0.00001 mg/kg) were combined to see if they would produce additive effects on memory enhancement. This strategy was successful in young monkeys with intact NE systems but was not effective in the aged monkeys. These findings demonstrate that drugs that indirectly stimulate postsynaptic alpha-2 receptors by increasing NE release are not as reliable in aged monkeys as directly acting agonists that can replace NE at postsynaptic alpha-2 receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7905189     DOI: 10.1016/0197-4580(93)90044-c

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  23 in total

Review 1.  A neurochemical yin and yang: does serotonin activate and norepinephrine deactivate the prefrontal cortex?

Authors:  Paul J Fitzgerald
Journal:  Psychopharmacology (Berl)       Date:  2010-04-13       Impact factor: 4.530

2.  Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism.

Authors:  J S Schneider; J P Tinker; E Decamp
Journal:  Behav Brain Res       Date:  2010-03-27       Impact factor: 3.332

Review 3.  Physiological approaches to understanding molecular actions on dorsolateral prefrontal cortical neurons underlying higher cognitive processing.

Authors:  Min Wang; Amy F T Arnsten
Journal:  Dongwuxue Yanjiu       Date:  2015-11-18

4.  Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates.

Authors:  Emmanuel Decamp; Kathryn Clark; Jay S Schneider
Journal:  Eur J Neurosci       Date:  2011-08-23       Impact factor: 3.386

Review 5.  Molecular modulation of prefrontal cortex: rational development of treatments for psychiatric disorders.

Authors:  Nao J Gamo; Amy F T Arnsten
Journal:  Behav Neurosci       Date:  2011-06       Impact factor: 1.912

6.  Noradrenergic contributions to cue-driven risk-taking and impulsivity.

Authors:  Chloe S Chernoff; Tristan J Hynes; Catharine A Winstanley
Journal:  Psychopharmacology (Berl)       Date:  2021-03-02       Impact factor: 4.530

7.  Bidirectional pharmacological perturbations of the noradrenergic system differentially affect tactile detection.

Authors:  Jim McBurney-Lin; Yina Sun; Lucas S Tortorelli; Quynh Anh T Nguyen; Sachiko Haga-Yamanaka; Hongdian Yang
Journal:  Neuropharmacology       Date:  2020-05-21       Impact factor: 5.250

8.  Effects of nicotine and mecamylamine on cognition in rhesus monkeys.

Authors:  Simon N Katner; Sophia A Davis; Amber J Kirsten; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

9.  The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type.

Authors:  J T Coull; B J Sahakian; J R Hodges
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

Review 10.  A final common pathway for depression? Progress toward a general conceptual framework.

Authors:  Eric A Stone; Yan Lin; David Quartermain
Journal:  Neurosci Biobehav Rev       Date:  2007-10-10       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.